Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CMPX
CMPX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CMPX News
Compass Therapeutics Reports Q1 Results with Cash Runway Until 2028
5d ago
seekingalpha
Tovecimig Shows Significant Survival Benefit in Biliary Tract Cancer Trial
5d ago
Newsfilter
Pomerantz LLP Investigates Compass Therapeutics for Securities Fraud
Apr 30 2026
PRnewswire
Latest Developments in the Biotech Sector
Apr 30 2026
NASDAQ.COM
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
Apr 28 2026
Yahoo Finance
Compass Therapeutics Shares Plunge 66% After Clinical Trial Setback
Apr 27 2026
seekingalpha
High Options Volume for Compass Therapeutics and CVR Energy
Apr 27 2026
NASDAQ.COM
Compass Therapeutics Faces Investor Claims Investigation
Apr 27 2026
Globenewswire
Tovecimig Plus Paclitaxel Shows Significant Survival Benefit in BTC Study
Apr 27 2026
Newsfilter
Compass Therapeutics Reports on Tovecimig Clinical Trial Progress
Apr 27 2026
stocktwits
Compass Therapeutics Advances Clinical Trial for Biliary Tract Cancer
Apr 27 2026
NASDAQ.COM
Compass Therapeutics to Host Webcast on April 27, 2026
Apr 24 2026
Newsfilter
Rocket Lab and Compass Therapeutics Show Active Options Trading
Apr 16 2026
NASDAQ.COM
Surge in Options Trading Volume for Alphabet and Compass Therapeutics
Mar 31 2026
NASDAQ.COM
Compass Therapeutics Reports Q4 and Full Year 2025 Financial Results
Mar 05 2026
seekingalpha
Analysis of Growth Drivers in the Biliary Tract Cancer Market
Mar 02 2026
Newsfilter
Show More News
